Flags with the logos of the Danish drug maker Novo Nordisk, maker of the blockbuster diabetes and weight -los treatments Ozempic and Wegovy are photos while the company presents the annual report in Novo Nordisk in Bagvaerd, Denmark, on February 5, 2025.
Mads Claus Rasmussen | AFP | Getty images
Novo Nordisk reported a better increase in the net profit of the first quarter on Wednesday, but reduced his prediction of the sales growth of the entire year, because copycat medicine compounders have the demand for his Blockbuster Wegovy drugs for weight loss at work.
The net profit of the Danish pharmaceutical giant came at 29.03 billion Danish croner ($ 4.4 billion) for the period from three months to the end of March, prior to the 27.8 billion Danish croner prediction by analysts in an LSEG poll.
Shares of Novo Nordisk rose by 4.25% at 8:38 am London.
The sale of the popular Wegovy Obesity medication of the company rose annually by 83% against constant exchange rates to 17.36 billion Danish Kroner, just under 18.51 billion Danish Kroner who was expected by analysts in a fact set of Tuesday.
Overall weather at Novo Nordisk – who also produces diabetes and treatments for rare diseases – increased 18% to 78.09 billion Danish crown versus an expected 78.18 million Danish crown.
First quarter of the Ozempic Fix sales treatment in 32.72 billion Danish croner compared to predictions of 31.5 billion Danish crown.
Before 2025, the company now sees sales growth from 13% to 21% at constant exchange rates, under the earlier Previve prediction from 16% to 24% in February. The growth in operational profit is predicted at 16% to 24%, versus 19% to 27% earlier.
Novo Nordisk CEO Lars Fruerd Jørgensen attributed the reduced prediction to rising competition from composite weight loss medicines in the US
“In the first quarter of 2025 we brought 18% revenue growth and continued to expand the reach of our innovative LP-1 treatments,” Jørgensen said in a statement.
“However, we have reduced our prospects on the entire year due to the lower LP-planned brand LP
American composite pharmacies were allowed to make legal copies of Novo’s Wegovy and Diabetes -Medicijn Ozempic under a drug deficit that is due to the Food and Drug Administration (FDA).
The FDA in February stated that deficit, so that the composite pharmacies were given until 22 May to stop selling copies of the medicine. However, Jørgensen repeats on Wednesday that the company would chase companies that will continue to distribute such copycat medication illegally.
Heat competition
The results eat in the midst of the rotated demand for the Blockbuster Glyp-1weight loss treatments of the DRARUG maker, who work by simulating a hormone stiff glucon-like peptide-1 to suppress the appetite.
However, the company has difficulty shaking a negative sentiment after a series of disappointing test results for his next generation of obesity drur candidate Cagrisema.
Novo Nordisk confirmed on Wednesday that it is planning to submit the approval of Cagrisema in the first quarter of 2026. In the meantime, it has requested you for a regulating American Appal from an oral version of the existing semaglutide treatment, which it said to be obesity. “
Competition is heated in the weight loss market, with pharmaceutical companies, including Roast” Astrazeneca And Abbvie All all develop potential new candidates.
Novo’s most important American rival Eli Lilly reported on Thursday expectation on Thursday with an increase of 45% in the turnover of the first quarter, although Reves was slightly lower than expected for his popular weight-los drug drug. The American medicine maker also lowered his profit guidance for the entire year due to costs with regard to the recent deal for cancer treatment, which reduced shares.
